Navigation Links
Stem Cell Administration Study Demonstrates Improved Quality Of Life For Patients Suffering From Spinal Cord Injury
Date:3/12/2009

Patients Suffering from Acute and Chronic Spinal Cord Injury Regain Sensation, Motor Functions and Bladder Control According to a Safety and Feasibility Study Published Today in Cell Transplantation

DaVinci Biosciences, in collaboration with Luis Vernaza Hospital in Ecuador, announced today the publication of study results demonstrating the safety and feasibility of its acute and chronic spinal cord injury treatment platform in issue 17(12) of Cell Transplantation, a peer-reviewed journal focused on regenerative medicine. The study demonstrates that administering adult autologous bone marrow derived stem cells via multiple routes is feasible, safe, and most importantly, improves the quality of life for both acute and chronic spinal cord injury (SCI) patients.

The study documents eight patients (four acute and four chronic) who were administered autologous bone marrow derived stem cells using a multiple route delivery technique. A two-year follow-up was performed on all the patients in the study who received the treatment. Using sequential MRIs, the follow-up demonstrated noticeable morphological changes within the spinal cord after administration of autologous bone marrow derived stem cells. Participating spinal cord injury patients experienced varying degrees of improvement in their quality of life, such as increased bladder control, regained mobility and sensation. Most importantly, the study demonstrated no adverse effects such as tumor formation, increased pain, and/or deterioration of function following administration of autologous bone marrow derived stem cells. In a video provided by the Luis Vernaza Hospital, patients involved in the study can be seen discussing their improved quality of life at: http://bit.ly/DavinciStemCellStudy.

Up to 400,000 people in the United States are estimated to live with spinal cord injuries, according to the Christopher and Dana Reeve Foundation. On January 23, 2009, The Food and Drug Administration approved the first U.S. clinical trial to use human embryonic stem cells in paralyzed humans. In a recent ABC News story on this FDA approval, Dr. Sean Morrison, director at the University of Michigan Center for Stem Cell Biology was cited as saying that even if this study could restore partial spinal cord function or bladder function that it would be a really important advancement. The study published by DaVinci Biosciences and Luis Vernaza Hospital in Cell Transplantation, which used stem cells derived from the patient's own bone marrow, documents the restoration of significant movement, sensation, and bladder function in patients suffering from a spinal cord injury.

"This collaborative study with the Luis Vernaza Hospital is a significant milestone for patients suffering from spinal cord injury," said Dr. Rafael Gonzalez, Director of Research and Development for DaVinci Biosciences. "We are pleased to see the publication of our research; it represents a giant step in the process of improving the quality of life in people living with spinal cord injury and other neurodegenerative disorders." ws" timex="3/12/2009 9:31:15 AM" dirsub="(The outcome of this study is exciting ...)" id="7490" index="biology" dir="Stem Cell Administration Study Demonstrates Improved Quality Of Life For Patients Suffering From Spinal Cord Injury" dir2="Stem Cell Administration Study Demonstrates Improved Quality Of Life..." keywords1=",biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters" keywords="Stem,Cell,Administration,Study,Demonstrates,Improved,Quality,Of,Life,For,Patients,Suffering,From,Spinal,Cord,Injury" description=" ...The outcome of this study is exciting for...we plan on expanding and building upon the results...said Francisco Silva, President of DaVinci Biosciences..." url=u&"/biology-news-1/Multiple-route-bone-marrow-stem-cell-injections-show-promise-to-treat-spinal-cord-injury-7490-2/" title="Stem%20Cell%20Administration%20Study%20Demonstrates%20Improved%20Quality%20Of%20Life%20For%20Patients%20Suffering%20From%20Spinal%20Cord%20Injury" %> Stem Cell Administration Study Demonstrates Improved Quality Of Life... (Patients Suffering from Acute and Chronic...)
Stem Cell Administration Study Demonstrates Improved Quality Of Life For Patients Suffering From Spinal Cord Injury
Date:3/12/2009

"The outcome of this study is exciting for us and our patients; we plan on expanding and building upon the results," said Francisco Silva, President of DaVinci Biosciences. "We strongly believe that this an important first step for realizing the therapeutic application of stem cells for treating diseases and injuries such as spinal cord injury in humans."

"Although there have been numerous studies in animals demonstrating the benefits of stem cell treatment for the treatment of spinal cord injury, this is the first published study of its kind, it gives patients the possibility that their quality of life can be improved," said Dr. Paul Sanberg, Director of the Center of Excellence for Aging and Brain Repair at the University of South Florida. A survey of spinal cord injury patients conducted in 2004 illustrates that one of the most important aspects in improving their quality of life would be the ability to control bladder function. Patients involved in DaVinci Biosciences' study regained partial or full bladder function, bladder sensation and/or the active ability to void.

DaVinci Biosciences is currently developing cell-based therapeutics and small molecule compounds for the treatment and cure of paralysis caused by spinal cord injury, amyotrophic lateral sclerosis (ALS) and other human degenerative disorders. In tandem with the Company's advances in cell-based and small molecule therapies, DaVinci Biosciences along with its collaborator has patented a surgical technique for the effective delivery of therapies directly into the spinal cord.

About DaVinci Biosciences

DaVinci Biosciences LLC is a privately held company dedicated to advancing therapies that improve the quality of life for individuals suffering from trauma, disease and degenerative disorders. Through independent research and partnerships with universities, medical research institutions, and hospitals, DaVinci Biosciences continues to discover biological breakthroughs relating to and further improving the treatment of degenerative disorders and injury. DaVinci Biosciences is headquartered in Costa Mesa, California. Patients involved in DaVinci's study can be seen discussing their improved quality of life at: http://bit.ly/DavinciStemCellStudy. For more information please visit http://www.davincibiosciences.com.

About Cell Transplantation

Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants.
'/>"/>
DaVinci Biosciences

Related biology news :

1. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
2. Nicotinic receptors may be important targets for treatment of multiple addictions
3. Emphasis on conifer forests places multiple species at risk
4. For honey bee queens, multiple mating makes a difference
5. Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
6. New magnetic separation technique might detect multiple pathogens at once
7. The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source
8. Multiple species of bacteria may cause trachoma: Implications for treatment
9. Multiple resource management is focus of new technical report
10. Potential new target for multiple sclerosis therapy
11. Fast AFM probes measure multiple properties of biomolecules or materials simultaneously
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
(Date:2/23/2017)... San Antonio, TX (PRWEB) , ... February 23, ... ... and Drug Administration (FDA) de novo clearance to begin marketing the SPEAC® System, ... is indicated for adults at home or in healthcare facilities during periods of ...
(Date:2/23/2017)... ... ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC 501(c)3 non-profit, ... is to advance global health and highlight the greater good of clinical trial participation ... trial volunteer. The vision of GGI is to serve as a philanthropic connector between ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one ... been named Fellows of the Society this year, the Fellows Committee has announced. ... fields of optics, photonics, and imaging as well as their service to the ...
Breaking Biology Technology: